Remove Disease Remove Immune Response Remove Presentation
article thumbnail

How GPCR-targeting therapies are advancing the fight against inflammatory disease

Drug Target Review

In this article, Stephan Schann, Chief Scientific Officer at Domain Therapeutics , explains why this class of drug target is so useful despite the challenges they present. Yet although they are a proven drug target family with widespread utility, they remain largely underexplored for tackling inflammatory diseases.

article thumbnail

July Fellow's Spotlight on Alicer Andrew

keypoint

She works in the Institute of Virology, where she characterizes HIV-specific T cell responses in people living with HIV, and endometrial immune responses in the context of infectious diseases and infertility. see photo below)

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Leveraging agonist antibodies to address immunological diseases

Drug Target Review

Introduction Therapeutic antibodies have proven to be indispensable medicines for addressing the most debilitating diseases. Agonist antibodies of immune checkpoint regulators These represent a groundbreaking class of immunotherapeutic agents that mimic the natural function of endogenous ligands by binding to specific cell-surface receptors.

article thumbnail

Outsmarting immune suppression through GPCR innovation

Drug Target Review

These CCR8+ Tregs are known to suppress immune responses in the tumour microenvironment (TME), allowing cancers to grow unchecked. “DT-7012 This opens the door for a disease-modifying approach both as a monotherapy and in combination, expanding treatment options and offering new hope to millions of patients.”

article thumbnail

Advancements in hit identification for membrane protein drug discovery

Drug Target Review

The challenge of GPCR drug discovery G protein-coupled receptors (GPCRs) are one of the most desirable and challenging target classes in drug discovery, as their mutation can lead to a wide range of diseases such as cancer, cardiovascular disorders and neurological conditions.

article thumbnail

Aleta’s Novel T Cell Engagers

SugarCone Biotech

These agents simultaneously bind to a tumor-associated protein on cancer cells and the CD3 protein on T-cells, facilitating a targeted anti-cancer immune response. Consequently, these drugs have limited ability to keep patients disease-free and limited impact on patient survival.

article thumbnail

How GPCR agonists, including antibodies, are shaping the future of metabolic care

Drug Target Review

G protein-coupled receptors (GPCRs) represent a cornerstone of modern drug discovery due to their crucial role in regulating human physiology and their involvement in numerous diseases. The MC4R-based ConfoGen was used to immunize llamas, resulting in an immune response that generated a highly diverse panel of MC4R-specific agonists.